Drugs · acquisition-cost intelligence
Insulin Glargine
insulin glargine-yfgn· ingredient insulin glargine· INSULIN GLARGINE 100 [iU]/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$6.01
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other insulin glargine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Rezvoglar KwikPen | $5.92 | −$0.09530 |
| Lantus | $6.16 | +$0.14520 |
| BASAGLAR KwikPen | $20.93 | +$14.92 |
| Insulin glargine U-300 | $59.13 | +$53.12 |
Medicare Part D coverage · CY2026
On 102 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 55% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.